Cargando…

Effects of early vs delayed progression on clinical and economic outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first-line therapy: results from the IMPACT RCC claims data analysis

BACKGROUND: A key therapeutic goal of metastatic renal cell carcinoma (mRCC) treatment is delayed disease progression. The degree to which early therapeutic success affects downstream outcomes is not well established. OBJECTIVE: To assess the clinical and economic impact of early vs delayed disease...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hutson, Thomas E, Liu, Frank X, Dieyi, Christopher, Kim, Ruth, Krulewicz, Stan, Kasturi, Vijay, Bhanegaonkar, Abhijeet
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394198/ https://www.ncbi.nlm.nih.gov/pubmed/34165322 http://dx.doi.org/10.18553/jmcp.2021.20569

Ejemplares similares

Real-World Outcomes Among US Veterans Health Administration Patients Newly Diagnosed with Metastatic Renal Cell Carcinoma and Treated with First-Line Monotherapy
por: Bhanegaonkar, Abhijeet, et al.
Publicado: (2021)

Real‐World Clinical Outcomes in Patients with Locally Advanced or Metastatic Merkel Cell Carcinoma Treated in U.S. Oncology Clinical Practices: Results from SPEAR‐Merkel
por: Bhanegaonkar, Abhijeet, et al.
Publicado: (2021)

Clinical and Economic Outcomes in Patients With Metastatic Urothelial Carcinoma Receiving First-Line Systemic Treatment (the IMPACT UC I Study)
por: Bilen, Mehmet A, et al.
Publicado: (2023)

A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)
por: Molina, Ana M., et al.
Publicado: (2013)

Mechanisms of Acquired Resistance to Tyrosine Kinase Inhibitors in  Clear - Cell Renal Cell Carcinoma (ccRCC)
por: Bielecka, Zofia F., et al.
Publicado: (2013)

Budget Impact Of Including Avelumab As A Second-Line Treatment For Locally Advanced Or Metastatic Urothelial Cancer In The United States: Commercial And Medicare Payer Perspectives
por: Kongnakorn, Thitima, et al.
Publicado: (2019)

Systemic therapy in metastatic renal cell carcinoma (mRCC): an evidence-based recommendation of the German interdisciplinary RCC guidelines group
por: Grünwald, V., et al.
Publicado: (2022)

Development and Validation of an Inflammatory Bowel Disease Severity Index Using US Administrative Claims Data: A Retrospective Cohort Study
por: Chen, Grace, et al.
Publicado: (2020)

Treatment Sequencing Patterns in Patients with Metastatic Urothelial Cancer Treated in the Community Practice Setting in the United States: SPEAR-Bladder (Study informing treatment Pathway dEcision in bladder cAnceR)
por: Doshi, Gurjyot K, et al.
Publicado: (2020)

Allogeneic Stem Cell Transplantation for Metastatic Renal Cell Cancer (RCC)
por: Bregni, Marco, et al.
Publicado: (2011)

Sunitinib cause delayed complete response on metastatic RCC and extensive IVC thrombus, but not to the kidney tumor: a case report and review of literature
por: Beltagy, Ahmad, et al.
Publicado: (2019)

Validation of the post sleep questionnaire for assessing subjects with restless legs syndrome: results from two double-blind, multicenter, placebo-controlled clinical trials
por: Canafax, Daniel M, et al.
Publicado: (2011)

Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)
por: Harrison, Michael R., et al.
Publicado: (2021)

Economic value of atopic dermatitis prevention via infant formula use in high-risk Malaysian infants
por: Bhanegaonkar, Abhijeet J, et al.
Publicado: (2015)

Clinical and Pathological Complete Remission in a Patient With Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: Is mRCC Curable With Targeted Therapy?
por: Shah, Amishi Y., et al.
Publicado: (2015)

Giant Renal Cell Carcinoma (RCC): A Case Report of Delayed Diagnosis and Management
por: Villacreses, Camila A, et al.
Publicado: (2023)

Use of Open Claims vs Closed Claims in Health Outcomes Research
por: Baser, Onur, et al.
Publicado: (2023)

Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC—A Possible Path Forward
por: Harshman, L.C., et al.
Publicado: (2017)

A New Treatment Landscape for RCC: Association of the Human Microbiome with Improved Outcomes in RCC
por: Piao, Xuan-Mei, et al.
Publicado: (2023)

Molecular subtypes and prognosis in RCC
por: Beuselinck, Benoit, et al.
Publicado: (2015)

Open Surgery for Localized RCC
por: Vander Eeckt, Kathy, et al.
Publicado: (2007)

Urine Metabolomics for Renal Cell Carcinoma (RCC) Prediction: Tryptophan Metabolism as an Important Pathway in RCC
por: Liu, Xiaoyan, et al.
Publicado: (2019)

Integrative Analysis of DNA Methylation Identified 12 Signature Genes Specific to Metastatic ccRCC
por: Qian, Siwei, et al.
Publicado: (2020)

SUN-479 Metastatic Renal Cell Carcinoma (RCC) to the Thyroid: Case Report and Clinical Lesson
por: Reddy, Sreedevi Singidi, et al.
Publicado: (2020)

Balancing efficacy and quality of life measurements among metastatic renal cell carcinoma (RCC) studies
por: Aragon-Ching, Jeanny B.
Publicado: (2021)

A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience
por: Costello, Brian A., et al.
Publicado: (2022)

Untangling ccRCC prognosis with SLINKY
por: Reinfeld, Bradley I., et al.
Publicado: (2017)

The Multifaceted Roles of RCC1 in Tumorigenesis
por: Ren, Xuanqi, et al.
Publicado: (2020)

Sunitinib Enables a Clinical and Pathological Complete Remission of Metastatic Renal Cell Carcinoma (mRCC)
por: Peng, Bo, et al.
Publicado: (2017)

Expression of RSK4, CD44 and MMP-9 is upregulated and positively correlated in metastatic ccRCC
por: Ma, Jing, et al.
Publicado: (2020)

Clearing up Clear Cell: Clarifying the Immuno-Oncology Treatment Landscape for Metastatic Clear Cell RCC
por: Doppalapudi, Sai Krishnaraya, et al.
Publicado: (2021)

Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model
por: Yuen, J S P, et al.
Publicado: (2011)

Risk of infections in renal cell carcinoma (RCC) and non-RCC patients treated with mammalian target of rapamycin inhibitors
por: Kaymakcalan, M D, et al.
Publicado: (2013)

The treatment of primary and metastatic renal cell carcinoma (RCC) with image-guided stereotactic body radiation therapy (SBRT)
por: Teh, BS, et al.
Publicado: (2007)

Nephrectomy Delay of More than 10 Weeks from Diagnosis Is Associated with Decreased Overall Survival in pT3 RCC
por: Zeng, Jiping, et al.
Publicado: (2021)

Isolated Scalp Nodule in Patient with Undiagnosed RCC
por: Pan, David, et al.
Publicado: (2006)

Identification of RCC Subtype-Specific microRNAs–Meta-Analysis of High-Throughput RCC Tumor microRNA Expression Data
por: Kajdasz, Arkadiusz, et al.
Publicado: (2021)

RCC Real-World Data: Prognostic Factors and Risk Stratification in the Immunotherapy Era
por: Sagie, Shira, et al.
Publicado: (2022)

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
por: Rini, Brian I., et al.
Publicado: (2019)

Identification of tyrosine kinase inhibitors that halt Plasmodium falciparum parasitemia
por: Kesely, Kristina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i82gbl9a2g4nkiqsgi20v43j2o